Peter F. Lenehan, MD, PhD

Areas of expertise: Clinical Development; pre-clinical-to-clinical stage transition of anti-cancer compound development; molecular biology

Dr. Lenehan is a uniquely qualified physician-scientist and senior executive with broad experience in molecular biology, oncology and cardiovascular biotechnology, anti-cancer targeted pharmaceutical drug development, academia, and laboratory research who is engaged in and can effectively view translational medicine from scientific, clinical, and business perspectives. He is a critical thinker and skilled communicator who is particularly adept at conveying cutting edge advances in cancer genomics, emerging anti-cancer therapies, and cardiovascular risk assessment to his colleagues, outside investigators, and consultancy clients. A proven leader and effective manager, Peter is well versed in Phase I, II, and III clinical trial design/conduction and international regulatory strategies, including those for FDA’s IND, NDA, Pre-Sub, 510(k), and De Novo submissions, and EU’s medical device directives, including CE Mark.

Peter received his MD and PhD from the State University of New York Downstate Medical Center, Brooklyn, NY, having conducted his doctoral research in complement-dependent cytotoxicity in human leukemia, in part, in the Laboratory of Complement and Effector Biology at Memorial Sloan-Kettering Cancer Center, New York, NY. After completing an Internal Medicine residency at Thomas Jefferson University in Philadelphia and a Hematology/Oncology Fellowship at the University of Maryland Cancer Center in Baltimore, he joined the faculty of the University of Maryland, Baltimore. There, he continued his leukemia research, now aimed at defining the biochemical mechanisms of non-P-glycoprotein mediated multi-drug resistance.

Subsequently, Dr. Lenehan spent 12 years at Pfizer Global Research & Development (legacy Warner-Lambert/Parke-Davis) in Ann Arbor, MI, where he led multiple international teams in the early phase oncology clinical development of numerous investigational anti-cancer compounds, including a radiosensitizer and multiple targeted kinase inhibitors. Currently, Peter is Chief Medical Officer of Everist Genomics, Inc (aka Everist Health), focusing on integrating the measurement of endothelial function into the assessment of general cardiovascular health by employing the company’s AngioDefender device and Vascular Age Calculator software application. He has published more than 50 manuscripts and abstracts and is co-inventor on 3 US patents.